Literature DB >> 3547614

Antacids for peptic ulcer: do we have anything better?

A Berstad, R Weberg.   

Abstract

During recent years several reports have appeared documenting that antacids containing aluminium hydroxide accelerate the healing process of duodenal ulcer. In gastric ulcer, however, only one study has demonstrated an effect clearly superior to that of placebo. Several studies, in both gastric and duodenal ulcer patients, have not been able to demonstrate any significant difference between antacids and H2 blockers with respect to ulcer healing and symptom relief. An important acknowledgement is the fact that the doses of antacids required for ulcer healing are much smaller than first assumed, and that tablet formulations of antacids are at least as effective as liquid antacid suspensions. The excellent effect of the more convenient low-dose tablet regimens has strengthened the position of antacids in the competition with other anti-ulcer drugs. Usually, side effects of low-dose antacid regimens are few and mild. In patients with impaired renal function, accumulation of absorbed aluminium may have serious consequences. However, in patients with healthy kidneys, aluminium is quickly excreted after absorption, and unhealthy effects are not documented. Antacids should therefore still constitute a cornerstone in the treatment of peptic ulcers.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3547614     DOI: 10.3109/00365528609093815

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  4 in total

Review 1.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

2.  Healing of chronic gastroduodenal ulcerations by antacids. Role of prostaglandins and epidermal growth factor.

Authors:  S J Konturek; T Brzozowski; D Drozdowicz; A Dembinski; C Nauert
Journal:  Dig Dis Sci       Date:  1990-09       Impact factor: 3.199

3.  Can restrictions on reimbursement for anti-ulcer drugs decrease Medicaid pharmacy costs without increasing hospitalizations?

Authors:  D M Cromwell; E B Bass; E P Steinberg; Y Yasui; W J Ravich; T R Hendrix; S F McLeod; R D Moore
Journal:  Health Serv Res       Date:  1999-02       Impact factor: 3.402

4.  Very-low dose antacid in treatment of duodenal ulcer. Comparison with cimetidine.

Authors:  S Zaterka; F Cordeiro; L G Lyra; M M Toletino; S J Miszputen; J L Jorge; E P Silva; F E Vieira; J L Modena; H K Massuda
Journal:  Dig Dis Sci       Date:  1991-10       Impact factor: 3.199

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.